CytoMed Therapeutics Limited (GDTC) AI Stock Analysis

• Market Cap: $26.77M
• Dividend Yield: N/A
• Average Volume (3M): 26.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.42
• Revenue Growth: N/A
• EPS Growth: 38.80%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.16
• Shares Outstanding: 11,540,000
• 10 Day Avg. Volume: 12,905
• 30 Day Avg. Volume: 26,636
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.34
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 168.89
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

CytoMed Therapeutics Limited is facing significant financial challenges, with substantial declines in revenue and persistent losses. The technical indicators suggest a bearish trend with potential short-term opportunities due to oversold conditions. Valuation metrics, including a negative P/E ratio, reflect poor profitability and lack of dividend yield. These factors contribute to a low overall stock score, highlighting the need for improved financial strategies and market conditions to enhance investor confidence.

CytoMed Therapeutics Limited Business Overview & Revenue Model

Company Description

CytoMed Therapeutics Limited (GDTC) is a biotechnology company focused on the development and commercialization of innovative cell-based therapies for the treatment of various diseases. The company is engaged in research and development activities primarily in the field of regenerative medicine, using advanced cellular technologies to address unmet medical needs. CytoMed's core products include a pipeline of therapeutic candidates designed to harness the power of cellular therapy to restore health and improve patient outcomes.

How the Company Makes Money

CytoMed Therapeutics Limited generates revenue through the development and commercialization of its cell therapy products. The company invests in research and development to advance its pipeline of therapeutic candidates, which, once approved, are marketed and sold to healthcare providers and institutions. Revenue streams include product sales, potential licensing agreements, and strategic partnerships with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties. The company's financial success is contingent upon the successful approval and commercialization of its therapeutic candidates, as well as the establishment of collaborations with industry partners to enhance market reach and adoption.

CytoMed Therapeutics Limited Financial Statement Overview

Summary

The company exhibits a strong gross profit margin but struggles with significant operational losses, negative net income, and cash flow issues. The balance sheet shows low leverage but a heavy reliance on equity financing, indicating financial stability but also potential risks.

Income Statement

The company reported a revenue of $290,560 with a gross profit of $213,091, reflecting a gross profit margin of 73.34%. However, the company is operating at a net loss with a net income of -$3,131,788, resulting in a negative net profit margin. Both EBIT and EBITDA margins are negative, indicating challenges in covering operational costs.

Balance Sheet

The company has a strong equity base with stockholders' equity of $8,492,291 and low total debt of $448,022, resulting in a low debt-to-equity ratio of 0.05. However, the company's high reliance on equity financing may pose a risk if equity markets are unfavorable.

Cash Flow

The operating cash flow is negative at -$2,601,298, indicating the company is burning cash. The lack of available free cash flow data limits further analysis, but the heavy reliance on financing cash flow suggests potential liquidity concerns.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
290.56K	―	―	―	0.00
	Gross Profit
213.09K	―	―	―	0.00
	EBIT
-2.91M	―	―	―	―
	EBITDA
-2.94M	―	―	―	―
	Net Income Common Stockholders
-3.13M	―	―	―	―
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.00M	―	―	―	―
	Total Assets
12.37M	―	―	―	―
	Total Debt
448.02K	―	―	―	―
	Net Debt
-8.55M	―	―	―	―
	Total Liabilities
1.12M	―	―	―	―
	Stockholders Equity
8.49M	―	―	―	―
Cash Flow		Free Cash Flow
―	―	―	―	―
	Operating Cash Flow
-2.60M	―	―	―	―
	Investing Cash Flow
―	―	―	―	―
	Financing Cash Flow
8.27M	―	―	―	―

CytoMed Therapeutics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDTC, the sentiment is Negative. The current price of 2.3 is below the 20-day moving average (MA) of 2.39, below the 50-day MA of 2.51, and above the 200-day MA of 2.28, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 46.06 is Neutral, neither overbought nor oversold. The STOCH value of 39.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GDTC.

CytoMed Therapeutics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.36B	3.88	-42.93%	2.87%	17.85%	1.45%
BRNS	47 Neutral	$36.69M	―	-38.49%	―	1773.18%	19.16%
VYNE	43 Neutral	$20.84M	―	-56.54%	―	18.16%	86.65%
GDTC	41 Neutral	$26.77M	―	-24.97%	―	―	38.80%
PYPD	41 Neutral	$28.43M	―	-1038.73%	―	―	34.97%
TPST	39 Underperform	$25.55M	―	-182.35%	―	―	-220.54%
CLNN	39 Underperform	$26.52M	―	-1738.36%	―	-47.71%	-244.00%